Experience
Roger Franklin (born 1979) holds a Ph.D. in oncology from the University of Cambridge. Roger has more than 15 years of experience from the life science industry, including positions as senior analyst in pharmaceuticals and biotech at a London-based investment bank and as investment manager at a large London-based life science venture capital fund. Roger currently serves as Partner at Hadean Ventures, a Stockholm/Oslo-based European life science venture fund.
Other assignments
Board Director of Abliva AB (Sweden) and TargED Biopharmaceuticals BV (Netherlands)
Board Observer at Pipeline Therapeutics Inc, San Diego (USA), Step Pharma SAS (France), Emergence Therapeutics AG (Germany), and Cardior Pharmaceuticals GmbH (Germany)
Experience
David Colpman (born 1961) has more than 30 years of biopharma business development and strategy experience, including as Head of Global Business Development at Shire Pharmaceuticals LLC where he led a series of strategic mergers, acquisitions, licensing and divestment programs. David has also held senior business development roles with Novo Nordisk A/S, Boots Pharmaceuticals and GlaxoSmithKline Plc.
Other assignments
Board Director of BerGenBio ASA (Norway), Elutia Inc (USA) and Oak Hill Bio Ltd. (UK), Advisor to Norgine Ltd (UK)
Experience
Cristina Csimma (born 1959) holds a PharmD from Massachusetts College of Pharmacy and an MHP from Northeastern University. Cristina has over 30 years of experience in drug development, company formation, and venture capital, and deep expertise in the U.S. biotech capital market. Past roles include serving as Executive Chair of Forendo Pharma, Exonics Therapeutics, and Sardona Therapeutics, and as Chair of Caraway Therapeutics. She also served as the founding President and CEO of Cydan. Previous board roles at Aceragen Inc., Palisade Bio, Juniper Pharma, Vtesse, and the T1D Exchange, as well as advisory work with the NIH.
Other assignments
Board Director of Asgard Therapeutics AB and Syncona Ltd (UK), Board Manager of New York Blood Center Ventures (US)
Experience
Charlotte Edenius (born 1958), M.D, Ph.D., is one of the co-founders of Gesynta Pharma and VP R&D Strategy. Charlotte has 30 years of experience from positions within the life science industry with experience from all phases of drug development as well as business development including successful partnering and licensing. Her experience spans from AstraZeneca to biotech companies including senior management positions as EVP R&D, Medivir AB, SVP Research, Orexo AB, and CSO, Biolipox AB. Charlotte has also served in non-executive board positions in several private and public pharma companies, including Kancera AB, Karolinska Development AB, and Immunicum AB.
Other assignments
Chairman of the Board and CEO of Allmora Life Science AB
Experience
Kristina Ekberg (born 1978) holds an LLM degree from Gothenburg University. As a partner at the Swedish law firm Vinge, Kristina led the Life Sciences and Health sector group and was part of the M&A practice group. Kristina currently serves as partner at HealthCap, a European venture capital firm investing globally in life sciences.
Other assignments
Board Director of Small Tx (HealthCap Development I) and various board assignments in the HealthCap group
Experience
Jonas Jendi (born 1970) holds an M.Sc. from the Stockholm School of Economics. Jonas joined Industrifonden in 2017. Jonas has been focused on the commercialization of life science innovation for about 20 years. Between 2001 and 2010, Jonas was the CEO of Cogmed, a start-up in the field of evidence-based cognitive training. Before joining Industrifonden, Jonas also held various advisor and board member roles in both early stage and public companies, and across digital health, medtech and biotech. Jonas is currently Practice Lead Life Science and Senior Investment Director at Industrifonden, where he also serves as COO.
Other assignments
Board Director of Airsonett AB, Asgard Therapeutics AB, Avidicare AB, Elypta AB, and Smartfish AS (Norway)
Experience
Pekka Simula (born 1974) holds an M.Sc. in Physics from Helsinki University of Technology. Pekka has more than 25 years of experience with innovative startups in health and life sciences, including digitalization of data capture in clinical trials, cancer radiotherapy, and as founder and CEO in oncology and CNS drug development companies. Pekka currently serves as Partner at Innovestor Life Science, a Helsinki-based life science venture fund.
Other assignments
Chairman of the Board of Soihtu DTx (Finland), Kasvu Therapeutics (Finland), and HVR Cardio Oy (Finland)